Madan Jagasia, MD | Authors

GLENDALE PHARMACY

1122 N BRAND BLVD LBBY

Articles

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

July 02, 2000

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a